SYMBIOTEC PHARMALAB LIMITED
1,164.00
INR
-34.05
(-2.84%)
SYMBIOTEC PHARMALAB LIMITED
BSE:SYMBIOTEC
(Bombay Stock Exchange)
Recent
price
1,164.00
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
INR
•
in mil. unless spec.Working Capital
INR
•
in mil. unless spec.Growth Rates
INR
•
in mil. unless spec.Quarterly Revenue
INR
•
in mil. unless spec.Quarterly Earnings Per Share
INR
•
in mil. unless spec.Quarterly Dividends Per Share
INR
•
in mil. unless spec.- Similar Companies
- Business
- Symbiotec Pharmalab Limited is an India-based pharmaceutical company that specializes in the research, development, manufacture, and commercialization of steroid- and hormone-based Active Pharmaceutical Ingredients (APIs), high-potency active pharmaceutical ingredients (HPAPIs), and specialty finished dosage formulations. Founded in 1995 and headquartered in Indore, Madhya Pradesh, India, the company operates as an integrated pharmaceutical manufacturer and contract development and manufacturing organization (CDMO) serving generic drug manufacturers and innovator pharmaceutical companies across more than 50 countries, including key markets in North America, Europe, Latin America, the Asia-Pacific region, and the Middle East. The company structures its operations into three core business segments: Active Pharmaceutical Ingredients, Finished Dosage Formulations, and Contract Development and Manufacturing Services. The API division develops and manufactures an extensive portfolio of synthetic and fermentation-based compounds, including corticosteroids such as dexamethasone, betamethasone, hydrocortisone, methylprednisolone, prednisolone, budesonide, fluticasone propionate, mometasone furoate, and deflazacort; progestins and female hormones such as progesterone, medroxyprogesterone acetate, norethisterone, levonorgestrel, and drospirenone; estrogens including estradiol, estriol, and conjugated estrogens; androgenic steroids including testosterone and its ester derivatives; and specialized HPAPIs used in anti-inflammatory, respiratory, oncology, dermatological, and reproductive health therapies. The Finished Dosage Formulations division produces sterile injectables, lyophilized vials, ophthalmic suspensions, nasal sprays, topical creams, ointments, and oral solid tablets and capsules. The CDMO and custom synthesis division delivers specialized biotransformation and fermentation chemistry, route scouting, process engineering, analytical method development, scale-up, stability testing, and regulatory documentation services under current Good Manufacturing Practice (cGMP) standards. Symbiotec Pharmalab Limited operates state-of-the-art research and development centers and manufacturing campuses in Rau and the Special Economic Zone (SEZ) at Pithampur in Madhya Pradesh. Its manufacturing facilities maintain regulatory accreditations and compliance certifications from international regulatory bodies, including the United States Food and Drug Administration (US FDA), the European Directorate for the Quality of Medicines (EDQM), the World Health Organization (WHO-GMP), and the Central Drugs Standard Control Organisation (CDSCO) of India. In recent developments, Symbiotec Pharmalab Limited has executed strategic capacity expansion programs across its sterile injectable and high-containment HPAPI manufacturing lines to meet escalating worldwide demand for complex steroidal and respiratory therapies. Backed by institutional private equity investment, the company has expanded its international commercial footprint by submitting multiple new Drug Master Files (DMFs) and Certificates of Suitability (CEPs) in the United States and European Union. Additionally, the company has entered into multi-year commercial supply partnerships with global generic pharmaceutical enterprises for critical respiratory and ophthalmic APIs, commissioned enhanced microbial fermentation suites, and advanced capital expenditure initiatives aimed at integrating automated manufacturing systems and continuous green chemistry processes across its production facilities.